GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer
GSK has acquired exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal worth up to £268 million.
The agreement reinforces GSK's oncology pipeline and gives Syndivia the scale to progress its promising asset. The ADC, developed by the France-based biotech firm, has shown enhanced tumour reduction in preclinical studies while maintaining an encouraging safety profile.
GSK noted that the therapy addresses a significant unmet need, given the limited targeted treatment options for this advanced form of prostate cancer.
The deal reflects GSK's push to broaden its oncology pipeline.
Author's summary: GSK acquires rights to Syndivia's ADC asset.
More News
- VSee Awarded US Department of Health & Human Services FedRAMP High ATO
- Building Knowledge, Not Just Structures: Redefining the Architect’s Role in Times of Uncertainty
- Circleville Police Respond to 46 Calls Monday, Including Burglary, Thefts, and Multiple Crashes - Scioto Post
- Brantford, Six Nations police get provincial funding for mobile crisis response teams
- Banging bumper fun from 2000AD!
- Apple Hits $4 Trillion Market Value, Joining Nvidia and Microsoft
- Massa F1 court case is irrational. But it makes perfect sense
- Coalition demands parliamentary inquiry into CFMEU 'elements of criminal conduct'
- In Review: Big-Ass Sword by Andreas Butzbach
- Wayfair: Q3 Earnings Snapshot - WTOP News